Helixgate

Helixgate

Uncategorized

STAT+: Congress returns to a packed health care agenda

Published

on

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Trump deleted an AI image of himself on Truth Social looking a whole lot like Jesus after conservative Christians cried blasphemy. “It’s supposed to be me as a doctor,” Trump told reporters while stepping out of the Oval Office to get a McDonald’s delivery. Send news tips and surprising health care angles to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

Recess is over

Congress returns to a packed health care agenda after two weeks off. Here’s what to follow.

Continue to STAT+ to read the full story…

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Amgen shores up Tavneos’ FDA defense with Duke data analysis

Published

on

After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval.​ ​Read More

Continue Reading

Uncategorized

Chile offers new data on food warning label efficacy

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.

Read the rest…

Read More

Continue Reading

Uncategorized

Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win

Published

on

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

Continue Reading
Advertisement

Trending